Revised forecast
Fiscal year ending March 2027 · Full yearPrevious forecast published April 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
The earnings forecast announced in April 2026 has been revised upward to reflect strong progress in products including PADCEV and mirabegron, the impact of foreign exchange rates and steady progress in cost management.
Impairment loss on intangible assets associated with the discontinuation of development of the CYP17 lyase inhibitor ASP5541: ¥26.4 billion
| Item | Details |
|---|---|
| Net Sales | ¥2,220,000 million → ¥2,330,000 million（＋5.0％） |
| Operating profit | ¥395,000 million → ¥460,000 million（＋16.5％） |
| Profit attributable to owners of the parent | ¥300,000 million → ¥350,000 million（＋16.7％） |
| Net income per share | 167.46 Yen/sen → 195.22 Yen/sen |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Full year |
| Publication date of previous forecast | April 2026 |
| Previous-period results | Revenue ¥2,139,245 million, operating profit ¥382,633 million, profit before tax ¥376,587 million, profit for the period ¥291,575 million, basic earnings per share ¥162.77 |
| Reason for the revision | The earnings forecast announced in April 2026 has been revised upward to reflect strong progress in products including PADCEV and mirabegron, the impact of foreign exchange rates and steady progress in cost management. |
| Details and amount of extraordinary loss | Impairment loss on intangible assets associated with the discontinuation of development of the CYP17 lyase inhibitor ASP5541: ¥26.4 billion |
| Dividend forecast revision | No change (whether the dividend forecast has been revised from the most recently announced forecast: No) |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (1)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The revision reflects strong progress in products including PADCEV and mirabegron, the impact of foreign exchange rates and steady progress in cost management.